Immunome, Inc.
IMNM
$19.37
$2.2813.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.68M | 12.59M | 10.94M | 9.04M | 10.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.68M | 12.59M | 10.94M | 9.04M | 10.13M |
| Cost of Revenue | 174.41M | 162.41M | 151.05M | 129.54M | 91.29M |
| Gross Profit | -164.73M | -149.82M | -140.11M | -120.50M | -81.16M |
| SG&A Expenses | 42.12M | 40.70M | 37.64M | 32.96M | 30.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.53M | 203.12M | 188.69M | 162.50M | 121.84M |
| Operating Income | -206.85M | -190.53M | -177.75M | -153.46M | -111.71M |
| Income Before Tax | -222.74M | -212.39M | -205.11M | -292.96M | -305.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -222.74 | -212.39 | -205.11 | -292.96 | -305.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -222.74M | -212.39M | -205.11M | -292.96M | -305.35M |
| EBIT | -206.85M | -190.53M | -177.75M | -153.46M | -111.71M |
| EBITDA | -204.56M | -188.42M | -175.73M | -151.89M | -110.44M |
| EPS Basic | -2.95 | -3.08 | -3.19 | -5.17 | -6.06 |
| Normalized Basic EPS | -1.57 | -1.58 | -1.58 | -1.47 | -1.12 |
| EPS Diluted | -2.96 | -3.09 | -3.19 | -5.18 | -6.06 |
| Normalized Diluted EPS | -1.57 | -1.58 | -1.58 | -1.47 | -1.12 |
| Average Basic Shares Outstanding | 317.22M | 289.47M | 262.39M | 234.53M | 214.48M |
| Average Diluted Shares Outstanding | 317.22M | 289.47M | 262.39M | 234.53M | 214.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |